These are the same side effects encountered with CD47 blockers, so presumably, a combination of the two would not resolve them; currently, a trial of mogamulizumab in combination with magrolimab is in the recruitment phase for patients with R/R stage IB-IV MF or Sézary syndrome (NCT04541017) [62]. The gene discussed is CD47; the disease is mycosis fungoides.